Longboard Pharmaceuticals, Inc. Research and Development Expense
Longboard Pharmaceuticals, Inc. reported Research and Development Expense of $21.45 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2024-11-07
- Longboard Pharmaceuticals, Inc. research and development expense for the quarter ending 2024-09-30 was $21.45M, a 104.52% increase year-over-year.
- Longboard Pharmaceuticals, Inc. research and development expense for the quarter ending 2024-06-30 was $20.45M, a 63.09% increase year-over-year.
- Longboard Pharmaceuticals, Inc. research and development expense for the quarter ending 2024-03-31 was $13.17M, a 54.40% increase year-over-year.
- Longboard Pharmaceuticals, Inc. research and development expense for the quarter ending 2023-12-31 was $12.20M, a 32.69% increase year-over-year.
- Longboard Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $43.75M, a 26.31% increase from fiscal 2022.
- Longboard Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $34.64M, a 75.17% increase from fiscal 2021.
- Longboard Pharmaceuticals, Inc. research and development expense for fiscal 2021 was $19.77M, a 326.81% increase from fiscal 2020.
- Longboard Pharmaceuticals, Inc. research and development expense for fiscal 2020 was $4.63M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2024-09-30 | $21.45M 10-Q · filed 2024-11-07 | $41.90M derived: sum of 2 quarters · filed 2024-11-07 | $55.06M 10-Q · filed 2024-11-07 | $67.26M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $20.45M 10-Q · filed 2024-08-01 | $33.62M 10-Q · filed 2024-08-01 | $45.81M derived: sum of 3 quarters · filed 2024-08-01 | $56.30M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | $13.17M 10-Q · filed 2024-05-02 | $25.37M derived: sum of 2 quarters · filed 2024-05-02 | $35.86M derived: sum of 3 quarters · filed 2024-11-07 | $48.39M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $12.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $22.69M derived: sum of 2 quarters · filed 2024-11-07 | $35.22M derived: sum of 3 quarters · filed 2024-11-07 | $43.75M 10-K · filed 2024-03-12 |
| 2023-09-30 | $10.49M 10-Q · filed 2024-11-07 | $23.02M derived: sum of 2 quarters · filed 2024-11-07 | $31.55M 10-Q · filed 2024-11-07 | $40.75M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $12.54M 10-Q · filed 2024-08-01 | $21.07M 10-Q · filed 2024-08-01 | $30.26M derived: sum of 3 quarters · filed 2024-08-01 | $39.66M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $8.53M 10-Q · filed 2024-05-02 | $17.72M derived: sum of 2 quarters · filed 2024-05-02 | $27.13M derived: sum of 3 quarters · filed 2024-05-02 | $36.05M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $9.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $18.60M derived: sum of 2 quarters · filed 2024-03-12 | $27.52M derived: sum of 3 quarters · filed 2024-03-12 | $34.64M 10-K · filed 2024-03-12 |
| 2022-09-30 | $9.40M 10-Q · filed 2023-11-02 | $18.32M derived: sum of 2 quarters · filed 2023-11-02 | $25.45M 10-Q · filed 2023-11-02 | $31.81M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $8.92M 10-Q · filed 2023-08-03 | $16.04M 10-Q · filed 2023-08-03 | $22.41M derived: sum of 3 quarters · filed 2023-08-03 | $26.50M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $7.12M 10-Q · filed 2023-05-09 | $13.49M derived: sum of 2 quarters · filed 2023-05-09 | $17.58M derived: sum of 3 quarters · filed 2023-05-09 | $22.50M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $6.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $10.46M derived: sum of 2 quarters · filed 2023-03-02 | $15.38M derived: sum of 3 quarters · filed 2023-03-02 | $19.77M 10-K · filed 2023-03-02 |
| 2021-09-30 | $4.09M 10-Q · filed 2022-11-03 | $9.01M derived: sum of 2 quarters · filed 2022-11-03 | $13.41M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $4.92M 10-Q · filed 2022-08-04 | $9.31M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $4.40M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $4.63M 10-K · filed 2022-03-03 | |||
| 2020-09-30 | $1.60M 10-Q · filed 2021-11-04 | $2.40M derived: sum of 2 quarters · filed 2021-11-04 | $2.46M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $800.00K 10-Q · filed 2021-08-09 | $859.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $59.00K 10-Q · filed 2021-05-10 |